Cat. No.: HY-66011A

Moxifloxacin

(Synonyms: BAY 12-8039 free base)

23 Cited Publications

Avis client

Based on 23 publication(s) in Google Scholar

Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.75%
CAS No.: 151096-09-2
Formule: C₂₁H₂₄FN₃O₄
Masse moléculaire:401.43

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Moxifloxacin Chemical Structure

CAS No.: 151096-09-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (23)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

Quinolone

Voir tous les produits spécifiques à Isoform Antibiotic :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	173 μM Compound: moxifloxacin	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
HEK293	IC₅₀	168.9 μM Compound: Moxifloxacin	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit	[PMID: 22761000]
HeLa	IC₅₀	110 μg/mL Compound: Moxifloxacin	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	320 μg/mL Compound: Moxifloxacin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	320 μM Compound: Moxifloxacin	Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
HEp-2	CC₅₀	>100 μM Compound: MXF	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 17228862]
HEp-2	CC₅₀	>100 μM Compound: MXF	Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay	[PMID: 21425851]
HEp-2	CC₅₀	>100 μM Compound: MXF	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 21443219]
HEp-2	CC₅₀	>100 μM Compound: moxifloxacin	Cytotoxicity against Hep2 cell line Cytotoxicity against Hep2 cell line	[PMID: 16337789]
HEp-2	CC₅₀	>100 μM Compound: moxifloxacin	Cytotoxicity against human Hep2 laryngeal carcinoma cell line Cytotoxicity against human Hep2 laryngeal carcinoma cell line	[PMID: 16337791]
Hepatocyte	CC₅₀	>100 μM Compound: MXF	Cytotoxicity against rat hepatocytes after 48 hrs Cytotoxicity against rat hepatocytes after 48 hrs	[PMID: 17228862]
HepG2	CC₅₀	>100 μM Compound: MXF	Cytotoxicity against human HepG2 cells after 72 hrs Cytotoxicity against human HepG2 cells after 72 hrs	[PMID: 17228862]
HepG2	EC₅₀	>100 μM Compound: 2	Cytotoxicity against human HepG2 cells after 72 hrs by CellTiter Glo assay Cytotoxicity against human HepG2 cells after 72 hrs by CellTiter Glo assay	[PMID: 33929852]
HepG2	IC₅₀	>50 μM Compound: Moxifloxacin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 35500229]
J774.A1	IC₅₀	14.56 μg/mL Compound: MOX	Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis	[PMID: 35486992]
K562	EC₅₀	>100 μM Compound: 2	Cytotoxicity against human K562 cells after 72 hrs by CellTiter Glo assay Cytotoxicity against human K562 cells after 72 hrs by CellTiter Glo assay	[PMID: 33929852]
L6	IC₅₀	5.7783 μM Compound: Moxifloxacin	Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay	[PMID: 32623216]
MDCK	CC₅₀	161 μM Compound: MXFX	Cytotoxicity against MDCK cells after 48 hrs by CPE assay Cytotoxicity against MDCK cells after 48 hrs by CPE assay	[PMID: 21481984]
MG-63	IC₅₀	170 μg/mL Compound: Moxifloxacin	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	230 μg/mL Compound: Moxifloxacin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	230 μM Compound: Moxifloxacin	Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
MRC5	IC₅₀	>100 μg/mL Compound: MOX	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis	[PMID: 35486992]
MRC5	IC₅₀	10.9 μM Compound: Moxifloxacin (MFLX)	In vitro inhibitory activity on MRC5 fibroblast tissue cultures inoculated with virulent RH strain of Toxoplasma gondii In vitro inhibitory activity on MRC5 fibroblast tissue cultures inoculated with virulent RH strain of Toxoplasma gondii	[PMID: 15125930]
NIH3T3	IC₅₀	379.82 μg/mL Compound: Moxifloxacin	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay	[PMID: 28174104]
Osteoblast	IC₅₀	>400 μg/mL Compound: Moxifloxacin	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	160 μg/mL Compound: Moxifloxacin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
THP-1	EC₅₀	5.07 mg/L Compound: Moxifloxacin	Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 10% FBS Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 10% FBS	[PMID: 20385862]
THP-1	EC₅₀	5.21 mg/L Compound: Moxifloxacin	Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 20% FBS Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 20% FBS	[PMID: 20385862]
THP-1	EC₅₀	8.09 mg/L Compound: Moxifloxacin	Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 2% FBS Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 2% FBS	[PMID: 20385862]
Vero	CC₅₀	128 μg/mL Compound: Moxifloxacin	Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay	[PMID: 31352245]
Vero	CC₅₀	128 μg/mL Compound: MXF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29227930]

In Vitro

The in vitro activities of Moxifloxacin and Amoxicillin are compared by time-kill curve and inhibition of intracellular growth experiments by using a model of bone marrow-derived mouse macrophages infected by L. monocytogenes EGDe. Moxifloxacin acts much more rapidly, beginning to exert its effects in the first 3 h and achieving complete broth sterilization within 24 h of incubation. Moxifloxacin appears to have a protective effect against macrophage lysis, as many cells are still viable after 24 h of incubation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

144 white male Wistar rats (18-22 weeks; 300-400 g) infected Stenotrophomonas maltophilia^[4]
Dosage:

12 mg/kg
Administration:

Intravenous injection; once per day, twice per day, three times per day; for 7 days
Result:

Showed considerably less bacterial overgrowth in the spleens and lungs and without being toxic.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 151096-09-2
Appearance Solid
Masse moléculaire 401.43
Formule C₂₁H₂₄FN₃O₄
Color White to yellow
SMILES

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N(C4)C[C@]5([H])[C@@]4([H])CCCN5)=C3OC)C1=O)O
Synonyms

BAY 12-8039 free base
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (23)

All

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Nat Microbiol

Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. [Abstract]

2023 Mar;8(3):410-423. PMID: 36759752
Nat Commun

Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]

2022 Mar 2;13(1):1116. PMID: 35236849
mLife

Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. [Abstract]

2025 Apr 15;4(2):155-168. PMID: 40313980
Cell Mol Life Sci

Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model. [Abstract]

2022 Jul 22;79(8):441. PMID: 35864358
Int J Pharm

Modelling lung permeability of pharmaceuticals: The effectiveness of biomimetic open tubular capillary electrochromatography and immobilised artificial membrane chromatography coupled with mass spectrometry. [Abstract]

2026 Jan 5:687:126356. PMID: 41205685
J Clin Microbiol

Luciferase reporter mycobacteriophage (TM4:: GeNL) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex. [Abstract]

2025 Aug 20:e0084125. PMID: 40833127
Antibiotics (Basel)

Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia-An In Vitro and In Vivo Study. [Abstract]

2022 Feb 1;11(2):192. PMID: 35203795
Molecules

Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]

2025 Mar 9;30(6):1224. PMID: 40142001
FASEB J

Moxifloxacin Inhibits Neutrophil Responses to Immune Complexes and Ameliorates Skin Inflammation in a Model of Pemphigoid Diseases. [Abstract]

2026 Feb 28;40(4):e71586. PMID: 41676900
Antimicrob Agents Chemother

Incorporation of macrophage immune stresses into an intracellular assay of drug tolerance in Mycobacterium tuberculosis. [Abstract]

2025 Sep 11:e0079525. PMID: 40934365
Antimicrob Agents Chemother

An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]

2025 Jul 2;69(7):e0024925. PMID: 40407337
Antimicrob Agents Chemother

TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus. [Abstract]

2024 Dec 5;68(12):e0094524. PMID: 39470202
Antimicrob Agents Chemother

Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus. [Abstract]

2024 Dec 5;68(12):e0105124. PMID: 39470195
Microbiol Spectr

Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]

2025 Jul;13(7):e0307424. PMID: 40387379
ACS Chem Biol

Investigate Natural Product Indolmycin and the Synthetically Improved Analogue Toward Antimycobacterial Agents. [Abstract]

2022 Jan 21;17(1):39-53. PMID: 34908399
Water

2025 Jun 6.
Infect Drug Resist

In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant Mycobacterium tuberculosis Isolated from Retreatment Tuberculosis Patients. [Abstract]

2021 Sep 14;14:3729-3736. PMID: 34548797
SSRN

2025 Oct 14.
SSRN

2025 Oct 20.
Authorea

2025 Sep 17.
bioRxiv

2024 Nov 06.
Universität zu Lübeck

2022.

Solvant et solubilité

In Vitro:

DMSO : 31.25 mg/mL (77.85 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4911 mL

12.4555 mL

24.9109 mL

5 mM

0.4982 mL

2.4911 mL

4.9822 mL

10 mM

0.2491 mL

1.2455 mL

2.4911 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (277 KB)
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88. [Content Brief]

[2]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702. [Content Brief]

[3]. Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39. [Content Brief]

[4]. Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4911 mL	12.4555 mL	24.9109 mL	62.2774 mL
	5 mM	0.4982 mL	2.4911 mL	4.9822 mL	12.4555 mL
	10 mM	0.2491 mL	1.2455 mL	2.4911 mL	6.2277 mL
	15 mM	0.1661 mL	0.8304 mL	1.6607 mL	4.1518 mL
	20 mM	0.1246 mL	0.6228 mL	1.2455 mL	3.1139 mL
	25 mM	0.0996 mL	0.4982 mL	0.9964 mL	2.4911 mL
	30 mM	0.0830 mL	0.4152 mL	0.8304 mL	2.0759 mL
	40 mM	0.0623 mL	0.3114 mL	0.6228 mL	1.5569 mL
	50 mM	0.0498 mL	0.2491 mL	0.4982 mL	1.2455 mL
	60 mM	0.0415 mL	0.2076 mL	0.4152 mL	1.0380 mL

Keywords

Moxifloxacin

23 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Moxifloxacin

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Publications Citing Use of MedChemExpress (MCE) Moxifloxacin

Voir tous les produits spécifiques à Isoform Antibiotic

Activité biologique

Chemical Information

Publications (23)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Moxifloxacin

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Publications Citing Use of MedChemExpress (MCE) Moxifloxacin

Voir tous les produits spécifiques à Isoform Antibiotic

Activité biologique

Chemical Information

Publications (23)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Moxifloxacin Related Classifications

HY-66011A Related Classifications